Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
This open-label, multicenter, Phase 2 trial, will assess the anti tumor activity, safety and
pharmacokinetics, of Panzem® NCD in patients with metastatic, docetaxel refractory,
androgen-independent prostate cancer.